ABSTRACT
Growth differentiation factor 11 (GDF11) and GDF8 (MSTN) are closely related TGF-ß family proteins that interact with nearly identical signaling receptors and antagonists. However, GDF11 appears to activate SMAD2/3 more potently than GDF8 in vitro and in vivo. The ligands possess divergent structural properties, whereby substituting unique GDF11 amino acids into GDF8 enhanced the activity of the resulting chimeric GDF8. We investigated potentially distinct endogenous activities of GDF11 and GDF8 in vivo by genetically modifying their mature signaling domains. Full recoding of GDF8 to that of GDF11 yielded mice lacking GDF8, with GDF11 levels â¼50-fold higher than normal, and exhibiting modestly decreased muscle mass, with no apparent negative impacts on health or survival. Substitution of two specific amino acids in the fingertip region of GDF11 with the corresponding GDF8 residues resulted in prenatal axial skeletal transformations, consistent with Gdf11-deficient mice, without apparent perturbation of skeletal or cardiac muscle development or homeostasis. These experiments uncover distinctive features between the GDF11 and GDF8 mature domains in vivo and identify a specific requirement for GDF11 in early-stage skeletal development.
Subject(s)
Bone Development , Growth Differentiation Factors , Muscle, Skeletal , Myostatin , Animals , Female , Mice , Pregnancy , Amino Acids/chemistry , Amino Acids/genetics , Bone Development/genetics , Bone Morphogenetic Proteins/genetics , Bone Morphogenetic Proteins/metabolism , Growth Differentiation Factors/genetics , Growth Differentiation Factors/chemistry , Muscle, Skeletal/growth & development , Muscle, Skeletal/metabolism , Myostatin/genetics , Myostatin/chemistry , Transforming Growth Factor beta/metabolismABSTRACT
Skeletal muscle is an important tissue in energy metabolism and athletic performance. The use of effective synthetic supplements and drugs to promote muscle growth is limited by various side effects. Moreover, their use is prohibited by anti-doping agencies; hence, natural alternatives are needed. Therefore, we evaluated the muscle growth effect of substances that can act like synthetic supplements from edible marine algae. First, we isolated six marine algal polyphenols belonging to the phlorotannin class, namely dieckol (DK), 2,7â³-phloroglucinol-6,6'-bieckol (PHB), phlorofucofuroeckol A (PFFA), 6,6'-bieckol (6,6-BK), pyrogallol-phloroglucinol-6,6'-bieckol (PPB), and phloroglucinol (PG) from an edible brown alga, Ecklonia cava and evaluated their effects on C2C12 myoblasts proliferation and differentiation. Of the six phlorotannin isolates evaluated, DK and PHB induced the highest degree of C2C12 myoblast proliferation. In addition, DK and PHB regulates myogenesis by down-regulating the Smad signaling, a negative regulator, and up-regulating the insulin-like growth factor-1 (IGF-1) signaling, a positive regulator. Interestingly, DK and PHB bind strongly to myostatin, which is an inhibitor of myoblast proliferation, while also binding to IGF-1 receptors. Moreover, they bind to IGF-1 receptor. These results suggest that DK and PHB are potential natural muscle building supplements and could be a safer alternative to synthetic drugs.
Subject(s)
Aquatic Organisms/chemistry , Cyanobacteria/chemistry , Insulin-Like Growth Factor I/metabolism , Muscle, Skeletal/growth & development , Polyphenols/pharmacology , Signal Transduction/drug effects , Smad Proteins/metabolism , Animals , Cell Line , Cell Proliferation/drug effects , Cell Survival/drug effects , Creatine Kinase, MM Form/metabolism , Mice , Molecular Docking Simulation , Muscle Cells/drug effects , Muscle Development/drug effects , Muscle, Skeletal/drug effects , Myostatin/chemistry , Myostatin/metabolism , Prohibitins , Receptor, IGF Type 1/chemistry , Receptor, IGF Type 1/metabolismABSTRACT
Growth differentiation factor 8 (GDF8), a.k.a. myostatin, is a member of the larger TGFß superfamily of signaling ligands. GDF8 has been well characterized as a negative regulator of muscle mass. After synthesis, GDF8 is held latent by a noncovalent complex between the N-terminal prodomain and the signaling ligand. Activation of latent GDF8 requires proteolytic cleavage of the prodomain at residue D99 by a member of the tolloid family of metalloproteases. While tolloid proteases cleave multiple substrates, they lack a conserved consensus sequence. Here, we investigate the tolloid cleavage site of the GDF8 prodomain to determine what residues contribute to tolloid recognition and subsequent proteolysis. Using sequential alanine mutations, we identified several residues adjacent to the scissile bond, including Y94, that when mutated, abolish tolloid-mediated activation of latent GDF8. Using the astacin domain of Tll1 (Tolloid Like 1) we determined that prodomain mutants were more resistant to proteolysis. Purified latent complexes harboring the prodomain mutations, D92A and Y94A, impeded activation by tolloid but could be fully activated under acidic conditions. Finally, we show that co-expression of GDF8 WT with prodomain mutants that were tolloid resistant, suppressed GDF8 activity. Taken together our data demonstrate that residues towards the N-terminus of the scissile bond are important for tolloid-mediated activation of GDF8 and that the tolloid-resistant version of the GDF8 prodomain can function dominant negative to WT GDF8.
Subject(s)
Alanine/metabolism , Aspartic Acid/metabolism , Myostatin/genetics , Tolloid-Like Metalloproteinases/genetics , Tyrosine/metabolism , Alanine/genetics , Amino Acid Sequence , Aspartic Acid/genetics , Cloning, Molecular , Escherichia coli/genetics , Escherichia coli/metabolism , Gene Expression Regulation , Genes, Reporter , Genetic Vectors/chemistry , Genetic Vectors/metabolism , HEK293 Cells , Humans , Luciferases/genetics , Luciferases/metabolism , Mutation , Myostatin/chemistry , Myostatin/metabolism , Protein Binding , Protein Interaction Domains and Motifs , Proteolysis , Signal Transduction , Tolloid-Like Metalloproteinases/chemistry , Tolloid-Like Metalloproteinases/metabolism , Tyrosine/geneticsABSTRACT
Channel catfish (Ictalurus punctatus) are one of the most important commercial freshwater fish in the world. China has been the major producer and consumer of channel catfish following the rapid development in the past three decades. In the present study, a novel orthologous myostatin gene, IpMSTNa, of channel catfish was identified based on homology cloning and genome locating. Multiple sequence alignments and gene structure analyses showed that the IpMSTNa gene and its deduced protein presented similar architectures to other known vertebrates. Phylogenetic and synteny analyses indicated that IpMSTNa belongs to MSTN1 orthologues. Pro-IpMSTNa protein is a typical disulphide-linked homodimer, with each chain containing an N-terminal pro-domain and a C-terminal unmatured GF domain, while pro-IpMSTNa present some significant differences in secondary structure and three-dimensional substances with pro-IpMSTNb. Relative expression level of the IpMSTNa gene upregulated rapidly and decreased dramatically during the embryonic and larval developmental stages, respectively. In addition, IpMSTNa displayed remarkably higher expression at most developmental stages compared to IpMSTNb. Tissue distribution analysis indicated that the IpMSTNa gene had a significantly higher level of expression than IpMSTNb in all selected tissues, with abundantly greater expression in the liver, muscle, gill and spleen, and moderately greater expression in the kidney, intestine, and head kidney. ISH analysis demonstrated that the expression signals of IpMSTNa and IpMSTNb at the selected developmental stages are consistent to qRT-PCR tests. Our study suggested that the IpMSTNa gene may have more biological functions, which have yet to be determined compared to the IpMSTNb gene.
Subject(s)
Ictaluridae/genetics , Myostatin/genetics , Sequence Homology, Nucleic Acid , Amino Acid Sequence , Animals , Base Sequence , Gene Expression Regulation, Developmental , Genomics , Humans , Ictaluridae/growth & development , Models, Molecular , Myostatin/chemistry , Myostatin/metabolism , Organ Specificity , Protein Conformation, alpha-HelicalABSTRACT
Myostatin (or growth/differentiation factor 8 (GDF8)) is a member of the transforming growth factor ß superfamily of growth factors and negatively regulates skeletal muscle growth. Its dysregulation is implicated in muscle wasting diseases. SRK-015 is a clinical-stage mAb that prevents extracellular proteolytic activation of pro- and latent myostatin. Here we used integrated structural and biochemical approaches to elucidate the molecular mechanism of antibody-mediated neutralization of pro-myostatin activation. The crystal structure of pro-myostatin in complex with 29H4-16 Fab, a high-affinity variant of SRK-015, at 2.79 Å resolution revealed that the antibody binds to a conformational epitope in the arm region of the prodomain distant from the proteolytic cleavage sites. This epitope is highly sequence-divergent, having only limited similarity to other closely related members of the transforming growth factor ß superfamily. Hydrogen/deuterium exchange MS experiments indicated that antibody binding induces conformational changes in pro- and latent myostatin that span the arm region, the loops contiguous to the protease cleavage sites, and the latency-associated structural elements. Moreover, negative-stain EM with full-length antibodies disclosed a stable, ring-like antigen-antibody structure in which the two Fab arms of a single antibody occupy the two arm regions of the prodomain in the pro- and latent myostatin homodimers, suggesting a 1:1 (antibody:myostatin homodimer) binding stoichiometry. These results suggest that SRK-015 binding stabilizes the latent conformation and limits the accessibility of protease cleavage sites within the prodomain. These findings shed light on approaches that specifically block the extracellular activation of growth factors by targeting their precursor forms.
Subject(s)
Antibodies, Monoclonal/chemistry , Antibodies, Neutralizing/chemistry , Molecular Docking Simulation , Myostatin/chemistry , Antibodies, Monoclonal/immunology , Antibodies, Neutralizing/immunology , Binding Sites , Humans , Myostatin/antagonists & inhibitors , Myostatin/immunology , Protein Binding , Protein StabilityABSTRACT
Biomolecule-derived peptides are attractive research resources to develop drugs and elucidate the basic mechanisms of life phenomena. This review article focuses on two biomolecules called "neuromedin U (NMU)" and "myostatin" that are deeply involved in obesity and muscle weakness caused by modern lifestyles and aging. A structure-activity relationship (SAR) study based on a biomolecule reveals the structural features required for the biological activity and gives clues leading the drug discovery process. NMU activates two types of receptors (NMUR1 and NMUR2). NMU, which is an attractive candidate for treating obesity, displays a variety of physiological actions in addition to appetite suppression. The discovery of useful receptor-selective agonists helps in elucidating the detailed roles of the respective receptors for each action and in developing therapeutic drugs based on receptor function. Hence, SAR studies focused on the amidated C-terminal heptapeptide of NMU were carried out to obtain selective agonists. Consequently, the respective hexapeptidic NMUR1 and NMUR2 agonists CPN-267 and CPN-116 were discovered. Myostatin, an endogenous negative regulator of skeletal muscle mass, is a promising target for treating muscle atrophy disorders. Focused on the inactivation mechanism of mature myostatin by the myostatin precursor-derived prodomain, a core peptide (23-mer) for effective myostatin inhibition was identified from the mouse myostatin prodomain sequence. The SAR study based on this core peptide afforded a 25-fold more potent derivative (16-mer), which increased skeletal muscle mass and hindlimb grip strength. Therefore, this derivative could be a novel platform for a peptidic drug useful in the treatment of muscle atrophy.
Subject(s)
Chemistry, Pharmaceutical , Drug Discovery , Myostatin/chemistry , Neuropeptides/chemistry , Peptides/chemistry , Aging , Humans , Life Style , Molecular Targeted Therapy , Muscle Weakness , Muscular Atrophy/therapy , Neuropeptides/therapeutic use , Obesity/drug therapy , Receptors, Neurotransmitter/agonists , Structure-Activity RelationshipABSTRACT
Growth differentiation factor 8 (GDF8; also known as myostatin) and GDF11 are closely related members of the transforming growth factor ß (TGF-ß) family. GDF8 strongly and negatively regulates skeletal muscle growth, and GDF11 has been implicated in various age-related pathologies such as cardiac hypertrophy. GDF8 and GDF11 signaling activities are controlled by the extracellular protein antagonists follistatin; follistatin-like 3 (FSTL3); and WAP, follistatin/kazal, immunoglobulin, Kunitz, and netrin domain-containing (WFIKKN). All of these proteins contain a follistatin domain (FSD) important for ligand binding and antagonism. Here, we investigated the structure and function of the FSD from murine WFIKKN2 and compared it with the FSDs of follistatin and FSTL3. Using native gel shift and surface plasmon resonance analyses, we determined that the WFIKKN2 FSD can interact with both GDF8 and GDF11 and block their interactions with the type II receptor activin A receptor type 2B (ActRIIB). Further, we solved the crystal structure of the WFIKKN2 FSD to 1.39 Å resolution and identified surface-exposed residues that, when substituted with alanine, reduce antagonism of GDF8 in full-length WFIKKN2. Comparison of the WFIKKN2 FSD with those of follistatin and FSTL3 revealed differences in both the FSD structure and position of residues within the domain that are important for ligand antagonism. Taken together, our results indicate that both WFIKKN and follistatin utilize their FSDs to block the type II receptor but do so via different binding interactions.
Subject(s)
Bone Morphogenetic Proteins/antagonists & inhibitors , Carrier Proteins/chemistry , Growth Differentiation Factors/antagonists & inhibitors , Myostatin/antagonists & inhibitors , Activin Receptors, Type II/chemistry , Activin Receptors, Type II/metabolism , Animals , Bone Morphogenetic Proteins/chemistry , Bone Morphogenetic Proteins/metabolism , Carrier Proteins/metabolism , Crystallography, X-Ray , Follistatin-Related Proteins/chemistry , Follistatin-Related Proteins/metabolism , Growth Differentiation Factors/chemistry , Growth Differentiation Factors/metabolism , HEK293 Cells , Humans , Intracellular Signaling Peptides and Proteins , Mice , Myostatin/chemistry , Myostatin/metabolism , Surface Plasmon ResonanceABSTRACT
Myostatin, a negative modulator of muscle growth, has been considered as a potential target for the treatment of type 2 diabetes (T2D). In previous work, it was found that myostatin inhibition by adeno-associated virus (AAV)-mediated gene delivery of myostatin propeptide (MPRO) could improve muscle mass and achieve therapeutic effects on glucose regulation and lipid metabolism in db/db mice. This study investigated whether pre-intervention of rAAV-mediated expression of MPRO could lower the incidence of T2D. Three-week-old male C57BL/6 mice were randomly divided into saline control, rAAV-GFP, and rAAV-MPRO groups, all of which were fed on a high-fat diet. It was observed that pre-intervention of rAAV-MPRO prevented high-fat diet-induced hyperglycemia and hyperlipidemia. It also improved glucose tolerance, downregulated serum insulin levels, and facilitated the growth of skeletal muscle and fat redistribution, with no significant difference in serum free fatty acid levels and body weight, which ultimately reduced the incidence of T2D. In addition, pretreatment of rAAV-MPRO in C2C12 cells increased insulin-stimulated glucose uptake, as well as glycogen synthesis under insulin resistance conditions induced by free fatty acids, with no significant difference in insulin-stimulated glucose oxidation. Finally, the study demonstrated that improved glucose metabolism by rAAV-MPRO pretreatment might be due to the activation of the PI3K/Akt/GSK3ß pathway and spurring Glut4 transposition from the cytoplasm to the cytomembrane in C2C12 cells. Based on these findings, MPRO is most likely to be a new method for the prevention of T2D.
Subject(s)
Dependovirus/genetics , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/therapy , Genetic Therapy , Genetic Vectors/genetics , Myostatin/genetics , Transgenes , Animals , Biomarkers , Blood Glucose , Cell Line , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Diet, High-Fat , Disease Models, Animal , Gene Expression , Genetic Therapy/methods , Glucose/metabolism , Humans , Incidence , Insulin/blood , Insulin Resistance , Lipids/blood , Male , Mice , Muscle, Skeletal/metabolism , Myostatin/chemistry , Phosphorylation , Signal Transduction , Tissue DistributionABSTRACT
Growth/differentiation factor 8 (GDF8), or myostatin, negatively regulates muscle mass. GDF8 is held in a latent state through interactions with its N-terminal prodomain, much like TGF-ß. Using a combination of small-angle X-ray scattering and mutagenesis, we characterized the interactions of GDF8 with its prodomain. Our results show that the prodomain:GDF8 complex can exist in a fully latent state and an activated or "triggered" state where the prodomain remains in complex with the mature domain. However, these states are not reversible, indicating the latent GDF8 is "spring-loaded." Structural analysis shows that the prodomain:GDF8 complex adopts an "open" configuration, distinct from the latency state of TGF-ß and more similar to the open state of Activin A and BMP9 (nonlatent complexes). We determined that GDF8 maintains similar features for latency, including the alpha-1 helix and fastener elements, and identified a series of mutations in the prodomain of GDF8 that alleviate latency, including I56E, which does not require activation by the protease Tolloid. In vivo, active GDF8 variants were potent negative regulators of muscle mass, compared with WT GDF8. Collectively, these results help characterize the latency and activation mechanisms of GDF8.
Subject(s)
Myostatin/chemistry , Activins/chemistry , Animals , Atrophy/pathology , Cell Differentiation , Dependovirus , Growth Differentiation Factor 2 , Growth Differentiation Factors/chemistry , HEK293 Cells , Humans , Hydrogen-Ion Concentration , Ligands , Male , Mice , Mice, Inbred C57BL , Mutagenesis , Mutation , Myostatin/genetics , Protein Domains , Scattering, Small Angle , Signal Transduction , Transforming Growth Factor beta/metabolismABSTRACT
Myostatin (MSTN), also called growth and differentiation factor-8 (GDF-8), is a member of the transforming growth factor-ß (TGF-ß) superfamily and an inhibitor of muscle differentiation and growth. In this report, we identified and characterized a MSTN gene (CnMSTN) from the scallop Chlamys nobilis. The open reading frame of CnMSTN was 1374bp in length, encoding 457 amino acids. The structure of CnMSTN included a putative signal peptide, a TGF-ß propeptide domain, and a conserved TGF-ß domain. Phylogenetic analysis showed that the CnMSTN gene was clustered in the same subgroup with the MSTN gene found in Mollusca. Quantitative real-time PCR showed that the CnMSTN gene was widely expressed in all tissues tested, with the highest expression level observed in the adductor muscle. Six single nucleotide polymorphisms (SNPs) were identified in the promoter region, but no SNP was detected in the exon regions. Association analysis showed that SNP g.-579A/C had significant effects on body mass, soft-tissue mass, and adductor muscle mass. The CC and AC genotypes of g.-579A/C had significantly higher growth trait values than that of genotype AA (P<0.05). These results suggest that CnMSTN could be used as a candidate gene for the selective breeding of C. nobilis.
Subject(s)
Myostatin/genetics , Pectinidae/growth & development , Pectinidae/genetics , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , DNA, Complementary/genetics , Gene Expression Regulation, Developmental , Genetic Association Studies , Myostatin/chemistry , Pectinidae/metabolism , Phylogeny , Polymorphism, Single Nucleotide , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Homology, Amino Acid , Tissue DistributionABSTRACT
Myostatin is an important member of the transforming growth factor (TGF) family that functions to regulate muscle growth in animals. In this study, the myostatin gene (FmMstn) and two slightly different (short and long forms) cDNAs of the banana shrimp Fenneropenaeus merguiensis were cloned and characterized. Similar to Mstn gene of the scallop, fish and mammal, FmMstn gene consists of 3 exons and 2 introns. The 2kb upstream promoter region of the FmMstn gene consists of putative response elements for myocyte enhancing factor (MEF2) and E-box factors. The longest open reading frame of the short Mstn consists of 1260bp encoding for a protein with 420 amino acid residues. The long FmMstn is almost identical to the short FmMstn with the exception of 8 amino acid insertions. FmMstn is most similar to the Mstn of Litopenaeus vannamei and Penaeus monodon sharing >92-98% amino acid sequence identity. Multiple sequence alignment results revealed high degree of amino acid conservation of the cysteine residues and mature peptide of the FmMstn with Mstn from other animals. FmMstn transcript was detected in the heart, muscle, optic nerve and thoracic ganglion. FmMstn transcript level in muscle is higher in early postmolt, decreases in intermolt and increases again towards ecdysis. Higher expression level of FmMstn is also observed in smaller shrimp of the same age. Knock-down of FmMstn gene by RNAi can cause a significant increase in molt cycle duration and failure of some shrimp to undergo ecdysis. Direct DNA sequencing results revealed that FmMstn gene is highly polymorphic and several potential SNPs have been identified. Some SNPs are associated with the size difference of the shrimp. In summary, the result of this study indicates that shrimp FmMstn gene is molt/growth-related and the presence of SNP suggests that it could be a candidate gene for shrimp genetic improvement research.
Subject(s)
Molting/genetics , Myostatin/genetics , Penaeidae/genetics , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , DNA, Complementary/genetics , Gene Expression Regulation , Gene Knockdown Techniques , Introns , Myostatin/chemistry , Penaeidae/metabolism , Phylogeny , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , RNA Interference , Sequence AlignmentABSTRACT
BACKGROUND: Growth/differentiation factor 8 (GDF8) and GDF11 are two highly similar members of the transforming growth factor ß (TGFß) family. While GDF8 has been recognized as a negative regulator of muscle growth and differentiation, there are conflicting studies on the function of GDF11 and whether GDF11 has beneficial effects on age-related dysfunction. To address whether GDF8 and GDF11 are functionally identical, we compared their signaling and structural properties. RESULTS: Here we show that, despite their high similarity, GDF11 is a more potent activator of SMAD2/3 and signals more effectively through the type I activin-like receptor kinase receptors ALK4/5/7 than GDF8. Resolution of the GDF11:FS288 complex, apo-GDF8, and apo-GDF11 crystal structures reveals unique properties of both ligands, specifically in the type I receptor binding site. Lastly, substitution of GDF11 residues into GDF8 confers enhanced activity to GDF8. CONCLUSIONS: These studies identify distinctive structural features of GDF11 that enhance its potency, relative to GDF8; however, the biological consequences of these differences remain to be determined.
Subject(s)
Bone Morphogenetic Proteins/chemistry , Growth Differentiation Factors/chemistry , Myostatin/chemistry , Myostatin/metabolism , Amino Acid Sequence , Animals , Bone Morphogenetic Proteins/antagonists & inhibitors , Bone Morphogenetic Proteins/metabolism , Cells, Cultured , Crystallography, X-Ray , Follistatin/metabolism , Genes, Reporter , Growth Differentiation Factors/antagonists & inhibitors , Growth Differentiation Factors/metabolism , Humans , Injections, Intravenous , Ligands , Luciferases/metabolism , Mice , Models, Molecular , Myoblasts/metabolism , Myocardium/metabolism , Myostatin/antagonists & inhibitors , Phosphorylation , Protein Binding , Protein Serine-Threonine Kinases/metabolism , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/metabolism , Sequence Alignment , Signal Transduction , Smad Proteins/metabolism , Structural Homology, Protein , Structure-Activity RelationshipABSTRACT
OBJECTIVE: Myostatin, a member of the transforming growth factor-ß family, contributes to joint deterioration in mice. Thus, we aimed to assess the correlation of myostatin concentrations with the presence and severity of knee osteoarthritis (OA). MATERIAL AND METHODS: We determined serum and synovial fluid (SF) myostatin concentrations in a population of 184 patients with knee OA and 109 healthy controls. RESULTS: The knee OA group presented with higher serum myostatin concentrations than the controls. Knee OA patients with KL grade 4 showed higher serum and SF myostatin concentrations compared with those with KL grade 2 and 3. Knee OA patients with KL grade 3 had higher serum and SF myostatin concentrations compared with those with KL grade 2. Serum and SF myostatin concentrations were significantly correlated with KL grading. CONCLUSION: Serum and SF myostatin concentrations were correlated with the presence and severity of knee OA.
Subject(s)
Myostatin/analysis , Osteoarthritis, Knee , Aged , Biomarkers/analysis , Biomarkers/blood , Biomarkers/chemistry , Case-Control Studies , Female , Humans , Male , Middle Aged , Myostatin/blood , Myostatin/chemistry , Osteoarthritis, Knee/blood , Osteoarthritis, Knee/diagnosis , Osteoarthritis, Knee/epidemiology , Osteoarthritis, Knee/metabolism , Severity of Illness Index , Synovial Fluid/chemistryABSTRACT
The NTR domain of WFIKKN1 protein has been shown to have significant affinity for the prodomain regions of promyostatin and latent myostatin but the biological significance of these interactions remained unclear. In view of its role as a myostatin antagonist, we tested the assumption that WFIKKN1 inhibits the release of myostatin from promyostatin and/or latent myostatin. WFIKKN1 was found to have no effect on processing of promyostatin by furin, the rate of cleavage of latent myostatin by BMP1, however, was significantly enhanced in the presence of WFIKKN1 and this enhancer activity was superstimulated by heparin. Unexpectedly, WFIKKN1 was also cleaved by BMP1 and our studies have shown that the KKN1 fragment generated by BMP1-cleavage of WFIKKN1 contributes most significantly to the observed enhancer activity. Analysis of a pro-TGF-ß -based homology model of homodimeric latent myostatin revealed that the BMP1-cleavage sites are buried and not readily accessible to BMP1. In view of this observation, the most plausible explanation for the BMP1-enhancer activity of the KKN1 fragment is that it shifts a conformational equilibrium of latent myostatin from the closed circular structure of the homodimer to a more open form, making the cleavage sites more accessible to BMP1. On the other hand, the observation that the enhancer activity of KKN1 is superstimulated in the presence of heparin is explained by the fact KKN1, latent myostatin, and BMP1 have affinity for heparin and these interactions with heparin increase the local concentrations of the reactants thereby facilitating the action of BMP1. ENZYMES: Furin: EC 3.4.21.75; BMP1, bone morphogentic protein 1 or procollagen C-endopeptidase: EC 3.4.24.19.
Subject(s)
Bone Morphogenetic Protein 1/metabolism , Carrier Proteins/metabolism , Myostatin/metabolism , Recombinant Proteins/metabolism , Animals , Binding Sites/genetics , Bone Morphogenetic Protein 1/genetics , Carrier Proteins/genetics , Cell Line , Furin/metabolism , Heparin/metabolism , Humans , Models, Molecular , Mutation , Myostatin/chemistry , Myostatin/genetics , Protein Binding , Protein Domains , Protein Multimerization , Protein Precursors/chemistry , Protein Precursors/genetics , Protein Precursors/metabolism , Recombinant Proteins/chemistryABSTRACT
Growth and differentiation factor 11 (GDF11) is a transforming growth factor ß superfamily member with a controversial role in aging processes. We have developed a highly specific LC-MS/MS assay to quantify GDF11, resolved from its homolog, myostatin (MSTN), based on unique amino acid sequence features. Here, we demonstrate that MSTN, but not GDF11, declines in healthy men throughout aging. Neither GDF11 nor MSTN levels differ as a function of age in healthy women. In an independent cohort of older adults with severe aortic stenosis, we show that individuals with higher GDF11 were more likely to be frail and have diabetes or prior cardiac conditions. Following valve replacement surgery, higher GDF11 at surgical baseline was associated with rehospitalization and multiple adverse events. Cumulatively, our results show that GDF11 levels do not decline throughout aging but are associated with comorbidity, frailty, and greater operative risk in older adults with cardiovascular disease.
Subject(s)
Aging/metabolism , Bone Morphogenetic Proteins/metabolism , Cardiovascular Diseases/metabolism , Growth Differentiation Factors/metabolism , Myostatin/metabolism , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Biomarkers/blood , Bone Morphogenetic Proteins/blood , Bone Morphogenetic Proteins/chemistry , Cardiovascular Diseases/blood , Cardiovascular Diseases/mortality , Chromatography, Liquid , Demography , Female , Growth Differentiation Factors/blood , Growth Differentiation Factors/chemistry , Humans , Male , Middle Aged , Myostatin/blood , Myostatin/chemistry , Risk Factors , Tandem Mass Spectrometry , Young AdultABSTRACT
Myostatin (MSTN), also referred to as growth and differentiation factor-8 (GDF-8), is a member of the transforming growth factor-ß superfamily (TGF-ß) and an important negative regulator for skeletal muscle development and growth in vertebrates. However, its function is not clear in invertebrates. In this study, we cloned and analyzed the MSTN gene (Aj-MSTN) from sea cucumber (Apostichopus japonicus). The full-length cDNA sequence of Aj-MSTN gene was composed of 2912bp, which contained a 5' UTR of 487bp, an ORF of 1356bp encoding 452 amino acids and a 3' UTR of 1069bp. The structure of Aj-MSTN included a putative signal peptide, a TGF-ß propeptide domain and a conserved TGF-ß domain. Phylogenetic analysis showed that the Aj-MSTN gene was clustered in the same subgroup with the MSTN-like gene found in Strongylocentrotus purpuratus. Quantitative real-time PCR detection results indicated that the Aj-MSTN gene expressed widely in adult tissues and the highest expression level was observed in the body wall. At different developmental stages, the expression levels were increased significantly at early auricularia and doliolaria stages, and reached the peak at juvenile stage. Six SNPs were identified in 5' flanking region and exons of the Aj-MSTN gene. Association analysis showed that SNP-1, SNP-2 and SNP-4 had significant effects on dry body weight. The results suggested that Aj-MSTN gene could be used as a candidate gene for the selective breeding of A. japonicus.
Subject(s)
Gene Expression Regulation, Developmental , Myostatin/genetics , Stichopus/growth & development , Stichopus/genetics , Amino Acid Sequence , Animals , Base Sequence , Myostatin/chemistry , Organ Specificity , Phylogeny , Polymorphism, Single NucleotideABSTRACT
Myostatin, encoded by the MSTN gene (previously GDF8), is a member of the transforming growth factor-ß superfamily, which normally acts to limit skeletal muscle mass by regulating the number and growth of muscle fibers. In this study, a total of 84 myostatin gene sequences with known complete coding regions (CDS) and corresponding amino acid sequences were analyzed from 17 species, and differentiation within and among species was studied using comparative genomics and bioinformatics. Characteristics of the nucleotide and amino acid sequences were also predicted. The results indicated that a total of 569 polymorphic sites, including 53 singleton variable sites and 516 parsimony informative sites, which could be sorted into 44 haplotypes, were detected from 17 species. Observed genetic diversity was higher among species than within species, and Vulpes lagopus was more polymorphic than other species. There was clear differentiation of the myostatin gene among species and the reconstructed phylogenetic tree was consistent with the NCBI taxonomy. The myostatin gene was 375-aa long in most species, except for Mus musculus (376 aa) and Danio rerio (373 aa). The amino acid sequences of myostatin were deemed hydrophilic, and had theoretical pI values of <7.0, mostly due to the acidic polypeptide. The instability index of the myostatin protein was 40.48-51.63, indicating that the polypeptide is not stable. The G+C content of the CDS nucleotide sequence in different species was 40.60-51.69%. The predicted promoter region of the Ovis aries myostatin gene was 150-220 bp upstream of the start codon.
Subject(s)
Myostatin/genetics , Open Reading Frames , Phylogeny , Animals , Base Composition , Conserved Sequence , Evolution, Molecular , Humans , Myostatin/chemistry , Promoter Regions, Genetic , Protein Stability , Sequence AlignmentABSTRACT
Myostatin (MSTN) is an important member of the transforming growth factor-ß (TGF-ß) superfamily and is a muscle growth inhibitor. In the present study, we cloned the Chinese perch MSTN cDNA sequence and analyzed its expression patterns under various conditions. The MSTN full cDNA sequence was 3347 bp long, including an open-reading frame of 1131 bp, which encoded 376 amino acids. Sequence analysis demonstrated that the MSTN shared a highly conserved signal peptide, a TGF-ß functional peptide, a hydrolytic site (RARR), and nine conservative cysteine residues with other members of the TGF-ß superfamily. Sequence alignment and phylogenetic tree analyses indicated that the MSTN had a close relationship with teleostean fish, but they are far separated from mammals. Real-time polymerase chain reaction analysis revealed that the MSTN was strongly expressed in the skeletal muscle and heart tissues. Temporal expression analysis demonstrated that the MSTN gene was expressed in very low levels, from 20 to 90 dph (post-hatching development), and was at its highest level at 150 dph (P < 0.05). The fasting-re-feeding experiment showed that the expression of the MSTN gene was initially decreased in response to a single meal, after seven days of fasting, and subsequently increased significantly, and finally decreased back to its original level. Together, our results provided valuable knowledge regarding the regulation of MSTN gene expression in Chinese perch.
Subject(s)
Fasting , Fish Proteins/genetics , Myostatin/genetics , Perches/metabolism , Amino Acid Motifs , Animals , Conserved Sequence , Fish Proteins/chemistry , Fish Proteins/metabolism , Gene Expression Regulation, Developmental , Heart/growth & development , Muscle, Skeletal/growth & development , Muscle, Skeletal/metabolism , Myocardium/metabolism , Myostatin/chemistry , Myostatin/metabolism , Open Reading Frames , Perches/genetics , Perches/physiologyABSTRACT
Growth differentiation factor 11 (GDF11) and myostatin (or GDF8) are closely related members of the transforming growth factor ß superfamily and are often perceived to serve similar or overlapping roles. Yet, despite commonalities in protein sequence, receptor utilization and signaling, accumulating evidence suggests that these 2 ligands can have distinct functions in many situations. GDF11 is essential for mammalian development and has been suggested to regulate aging of multiple tissues, whereas myostatin is a well-described negative regulator of postnatal skeletal and cardiac muscle mass and modulates metabolic processes. In this review, we discuss the biochemical regulation of GDF11 and myostatin and their functions in the heart, skeletal muscle, and brain. We also highlight recent clinical findings with respect to a potential role for GDF11 and/or myostatin in humans with heart disease. Finally, we address key outstanding questions related to GDF11 and myostatin dynamics and signaling during development, growth, and aging.
Subject(s)
Bone Morphogenetic Proteins/physiology , Growth Differentiation Factors/physiology , Myostatin/physiology , Adult , Aging/physiology , Amino Acid Sequence , Animals , Bone Morphogenetic Proteins/chemistry , Bone Morphogenetic Proteins/deficiency , Brain/growth & development , Brain/physiology , Dimerization , Female , Follistatin/metabolism , Follistatin-Related Proteins/metabolism , Growth Differentiation Factors/chemistry , Growth Differentiation Factors/deficiency , Growth Differentiation Factors/therapeutic use , Heart/physiology , Heart Diseases/metabolism , Humans , Male , Mice , Models, Molecular , Molecular Sequence Data , Muscles/physiology , Myocardium/metabolism , Myostatin/chemistry , Myostatin/deficiency , Organ Specificity , Protein Conformation , Protein Structure, Tertiary , Rats , Sequence Alignment , Sequence Homology, Amino Acid , Signal Transduction , Structure-Activity RelationshipABSTRACT
Myostatin (MSTN) is a potent negative regulator of skeletal muscle growth, and its activity is suppressed by MSTN propeptide (MSTNpro), the N-terminal part of MSTN precursor cleaved during post-translational MSTN processing. The current study examined which region of flatfish (Paralichthys olivaceus) MSTN-1 propeptide (MSTN1pro) is critical for MSTN inhibition. Six different truncated forms of MSTN1pro containing N-terminal maltose binding protein (MBP) as a fusion partner were expressed in Escherichia coli, and partially purified by an affinity chromatography for MSTN-inhibitory activity examination. Peptides covering different regions of flatfish MSTN1pro were also synthesized for MSTN-inhibitory activity examination. A MBP-fused MSTN1pro region consisting of residues 45-100 had the same MSTN-inhibitory potency as the full sequence flatfish MSTN1pro (residues 23-265), indicating that the region of flatfish MSTN1pro consisting of residues 45-100 is sufficient to maintain the full MSTN-inhibitory capacity. A MBP-fused MSTN1pro region consisting of residues 45-80 (Pro45-80) also showed MSTN-inhibitory activity with a lower potency, and the Pro45-80 demonstrated its MSTN binding capacity in a pull-down assay, indicating that the MSTN-inhibitory capacity of Pro45-80 is due to its binding to MSTN. Flatfish MSTN1pro synthetic peptides covering residues 45-65, 45-70, and 45-80 demonstrated MSTN-inhibitory activities, but not the synthetic peptide covering residues 45-54, indicating that residues 45-65 of flatfish MSTN1pro are essential for MSTN inhibition. In conclusion, current study show that like the mammalian MSTNpro, the MSTN-inhibitory region of flatfish MSTN1pro resides near its N-terminus, and imply that smaller sizes of MSTNpro can be effectively used in various applications designed for MSTN inhibition.